Cue Biopharma, Inc., a biopharmaceutical company, develops biologic drugs for the selective modulation of the human immune system to treat a range of cancers and autoimmune disorders. The company's lead drug candidate includes CUE-101, a variant form of the cytokine Interleukin-2 and a T cell antigen to target and activate T cells specific to human papilloma virus related cancers. Its biologics drug candidates also comprise CUE-100 series to improve various tumor specific T cells; and CUE-200 series to reinvigorate exhausted T cells. The company also offers MOD costimulatory optimization and discovery platform and viraTope T cell epitope discovery platform to develop novel biologics for addressing new indications in oncology and autoimmune disorders. Cue Biopharma, Inc. has collaboration agreements with Merck & Co. for the research and development of its proprietary biologics that target autoimmune disease indications; and Albert Einstein College of Medicine to develop Immuno-STAT biologics for chronic infectious diseases. It also has a strategic collaboration with LG Chem Life Sciences for Immuno- STATs biologics in oncology. The company was formerly known as Imagen Biopharma, Inc. and changed its name to Cue Biopharma, Inc. in October 2016. Cue Biopharma, Inc. was incorporated in 2014 and is based in Cambridge, Massachusetts. The company trades on NASDAQ exchange. The company headquarter is located in Cambridge, MA. The company was established in the 2014.

TickerCUE
Long NameCue Biopharma, Inc.
Short NameCue Biopharma